DrugPatentWatch Database Preview

CASPOFUNGIN ACETATE Drug Profile

« Back to Dashboard

Which patents cover Caspofungin Acetate, and when can generic versions of Caspofungin Acetate launch?

Caspofungin Acetate is a drug marketed by Cipla, Fresenius Kabi Usa, Gland Pharma Ltd, Mylan Labs Ltd, Sandoz Inc, and Xellia Pharms Aps. and is included in six NDAs. There is one patent protecting this drug.

This drug has fourteen patent family members in fourteen countries.

The generic ingredient in CASPOFUNGIN ACETATE is caspofungin acetate. There are eight drug master file entries for this compound. Nine suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the caspofungin acetate profile page.

Summary for CASPOFUNGIN ACETATE

International Patents:	14
US Patents:	1
Applicants:	6
NDAs:	6
Suppliers / Packagers:	8
Bulk Api Vendors:	35
Clinical Trials:	14
Patent Applications:	368
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for CASPOFUNGIN ACETATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CASPOFUNGIN ACETATE
Prior Art and Litigation Support	Order Prior Art and Litigation support for CASPOFUNGIN ACETATE
DailyMed Link:	CASPOFUNGIN ACETATE at DailyMed

Pharmacology for CASPOFUNGIN ACETATE

Drug Class

Echinocandin Antifungal

Synonyms for CASPOFUNGIN ACETATE

1-((4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine)-5-((3R)-3-hydroxy-L-ornithine)pneumocandin B0, diacetate (salt)

1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0 diacetate

1-[(4R,5S)-5-[(2-Aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0

1)-peptide diacetate salt

179463-17-3

463C173

AC-27763

AKOS025401982

AKOS026750216

AOB3093

C52H88N10O15.2C2H4O2

C56H96N10O19

Cancidas

Cancidas (TN)

Caspofungin (Acetate)

Caspofungin acetate (JAN/USAN)

Caspofungin acetate [USAN:BAN:JAN]

Caspofungin Acetate [USAN]

caspofungin diacetate

CHEBI:59900

CS-0578

D02501

HY-17006

J-011452

L 743,872

L 743872

L-743,872

L-743872

LS-173700

MK 0991

MK-0991

MK0991

MolPort-029-887-122

MolPort-035-395-717

MolPort-044-561-291

OGUJBRYAAJYXQP-LLXMLGLCSA-N

Pneumocandin B0, 1-((4R,5S)-5-((2-aminoethyl)amino)-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine)-5-((3R)-3-hydroxy-L-ornithine)-, diacetate (salt)

s3073

SCHEMBL149293

SW219088-1

UNII-VUW370O5QE

VUW370O5QE

W-5367

Y1176

US Patents and Regulatory Information for CASPOFUNGIN ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cipla	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	209489-001	Jul 12, 2018		DISCN	No	No
Mylan Labs Ltd	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	207650-001	Sep 29, 2017	AP	RX	No	No
Fresenius Kabi Usa	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	206110-002	Dec 30, 2016	AP	RX	No	No			Y
Xellia Pharms Aps	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	205923-002	Jul 2, 2018	AP	RX	No	No
Mylan Labs Ltd	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	207650-002	Sep 29, 2017	AP	RX	No	No
Cipla	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	209489-002	Jul 12, 2018		DISCN	No	No

International Patents for CASPOFUNGIN ACETATE

Country	Patent Number	Estimated Expiration
Poland	2922530
Denmark	2922530
Canada	2888625
Lithuania	2922530
Spain	2607646
Portugal	2922530

Supplementary Protection Certificates for CASPOFUNGIN ACETATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0620232	44/2001	Austria		PRODUCT NAME: CASPOFUNGIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE CASPOFUNGINACETAT; REGISTRATION NO/DATE: EU/01/196/001-003 20011024
0620232	2001/029	Ireland		PRODUCT NAME: CASPOFUNGIN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024; PAEDIATRIC INV. PLAN: P/30/2008
0620232	SPC/GB02/002	United Kingdom		A SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB02/002 GRANTED TO MERCK SHARP + DOHME, CORP IN RESPECT OF THE PRODUCT CASPOFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE, WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 5919 DATED 30 OCTOBER 2002 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 24 OCTOBER 2016.
0620232	C300076	Netherlands		PRODUCT NAME: CASPOFUNGINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT, IN HET BIJZONDER CASPOFUNGINE ACETAAT; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024
0620232	01C0054	France		PRODUCT NAME: CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001 20011024